GSK's 'Open Innovation' strategy to help deliver medicines to people in the world's poorest countries
UK drug giant GlaxoSmithKline's chief executive, Andrew Witty, yesterday announced a series of new initiatives targeted at further transforming the company's approach to diseases that disproportionately affect the world's poorest countries. His announcements, made at a meeting of the Council on Foreign Relations in New York, USA, build on commitments made in 2009 to work in partnership, expand access to medicines and encourage new research into neglected tropical diseases.
Mr Witty told his audience: 'We want to be a company that is truly a partner in addressing the health care challenges in the world's poorest countries, no matter how difficult they are. A restless company, never satisfied with what it has achieved, but always looking for ways of doing more.'
Welcomed by BIO
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze